Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SENATE

02 AUG 14 PM 4: 59

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Registrant Name Aventis Pharmaceuticals Inc. (former	erly known	as Aventis Pharma AG)	
2. Address Check if different than previously repo			
Principal Place of Business (if different from line 2) City: Washington		ip (or Country) DC 20004	
4. Contact Name Telep	hone	E-mail (optional)	5. Senate ID#
Eddie D. Evans (2	202) 898-3182		568:
7. Client Name 🖸 Self		•••	6. House ID#
			3518
10. Check if this is a Termination Report INCOME OR EXPENSES - Con			11. No Lobbyin
12. Lobbying Firms	***************************************	13. Orgai	nizations
INCOME relating to lobbying activities for thi period was:	s reporting	EXPENSES relating to lobbying period were:	activities for this rep
Less than \$10,000 🔲		Less than \$10,000 🚨	
\$10.000 or more □ ⇒ \$	<u> </u>	\$10,000 or more □ ⇒ \$	
Income (neare Provide a good faith estimate, rounded to the ne	arest \$20,000,	14. REPORTING METHOD. C accounting method. See instruction	
of all lobbying related income from the client payments to the registrant by any other entity		Method A. Reporting amounts using LDA defin	
activities on behalf of the client).		Method B. Reporting amoun Internal Revenue	
		Method C. Reporting amour Internal Revenue	
Signature			



Registrant Name	Aventis Pharmaceuticals Inc.	_ Client Name	self
engaged in lobbyir	_	the reporting peri	lect the general issue areas in which the a od. Using a separate page for each code
15. General issue	area code MMM (one pe	er page)	
16. Specific lobby	ving issues		
H.R. 4954 "Med All provisions	dicare Modernization and Prescriptio	n Drug Act of 2002"	
S. 2625 All provis	Medicare Outpatient Prosions	escription Dr	rug Act of 2002"
<u> </u>			
Senate House	Congress and Federal agencies co	ontacted	☐ Check if None
18. Name of each	n individual who acted as a lobby	vist in this issue a	rea
	Name		Covered Official Position (if applicable)
Judy Cook	, vario		Corcled Official A Satisfic (it approcasic)

Eddie Evans			

19. Interest of each	h foreign entity in the specific issue:	s listed on line 16 al	pove Check if None
Aventis SA is a s	tock corporation under French Comm	nercial law, headqua	artered in Strasbourg, France. Aventis Pharma create an awareness for the r
comprehensiv	ve medicare reform, and	the need to	provide access, through the poverage for prescriptions drug
Printed Name and	Title Eddie D. Evans, VP, Federa	il Government Relati	ions

Registrant Name	Aventis Pharmaceuticals Inc.	_ Client Name	self
engaged in lobbyir		the reporting perio	ect the general issue areas in which the red. Using a separate page for each code
15. General issue	area code LAW (one p	er page)	
H.R. 2341 "The All provisions	ring issues Class Action Fairness Act of 2002		
House	congress and Federal agencies congress and Federal agencies of the congress and Federal agencies agencies agencies agencies of the congress agencies agencies of the congress agencies of the congress agencies a		Check if None
10. Italie of cao.	Name		Covered Official Position (if applicable)
Aventis SA is a s	n foreign entity in the specific issu tock corporation under French Com SA. Aventis is interested in ensurin	mercial law, headquar	ove ☐ Check if None rtered in Strasbourg, France. Aventis Pharma tion lawsuits would be tried in a federal court.
Signatur e			Date
Printed Name and	Eddie D. Evans, VP, Feder	al Government Relation	



Registrant Name	Aventis Pharmaceuticals Inc.	_ Client Name	self
engaged in lobbyi	FIVITY. Select as many codes ng on behalf of the client during uested. Attach additional page(the reporting p	reflect the general issue areas in which the 1 eriod. Using a separate page for each code
15. General issue	area code LBR (one po	er page)	
All provisions	ying issues competition Act of 2001" Congress and Federal agencies co	ontacted	☐ Check if None
18. Name of each	h individual who acted as a lobb	yist in this issue	e area
	Name		Covered Official Position (if applicable)
Aventis SA is a s		mercial law, head	6 above ☐ Check if None quartered in Strasbourg, France. Aventis Pharma not enacted that would restrict legitimate transacti
Signature			Date
Printed Name and	Title Eddie D. Evans, VP, Federa	al Government Re	

· wgc .

Registrant Name	Aventis Pharmaceuticals Inc.	_ Client Name	self
engaged in lobbyi		the reporting period	ct the general issue areas in which the r l. Using a separate page for each code
15. General issue	area code TRD (one p	er page)	
S. 2244 "To pe	ying issues permit commercial importation of present commercial importation of presentation to the reimportation of presentation of presentati	cription drugs from Car	ada, and for other purposes"
17. House(s) of (Senate House	Congress and Federal agencies c	ontacted [Check if None
18. Name of eac	h individual who acted as a lobb	oyist in this issue are	a Covered Official Position (if applicable)
	матис		Covered Official Position (If applicable)
Judy Cook			
Eddie Evans			
Donald Zowader	.		

	ch foreign entity in the specific issu		
			ered in Strasbourg, France. Aventis Pharma ive effect this legislation could have on public
Signature			Date
Aventis SA is a is part of Aventis	stock corporation under French Com s SA. Aventis is interested because	nmercial law, headquar of the potentially negal	ered in Strasbourg, France. Aventis Phaive effect this legislation could have on p

Registrant Name	Aventis Pharmaceuticals Inc.	_Client Name	self
engaged in lobbyin		the reporting pe	reflect the general issue areas in which the reriod. Using a separate page for each code
15. General issue	area code _ PHA (one p	er page)	
16. Specific lobby H.R. 3448 "Pub All provisions re	ing issues lic Health Security and Bioterrorism elating to the Prescription Drug User	Preparedness an r Fee Act (PDUFA	d Response Act of 2002")
House Senate	ongress and Federal agencies c		☐ Check if None
18. Name of each	individual who acted as a lobb	yist in this issue	carea Covered Official Position (if applicable)
Judy Cook			Constant States (1. Epp. 1020.10)
Aventis SA is a st		mercial law, head	5 above ☐ Check if None quartered in Strasbourg, France. Aventis Pharma he Prescription Drug User Fee Act.
Sianat			Data
Signature	Eddie D. Evans, VP, Feder	al Government Pe	DateDate

rance a transfer

Registrant Name	Aventis Pharmaceuticals Inc.	Client Name	self
engaged in lobbyii		g the reporting p	reflect the general issue areas in which the 1 eriod. Using a separate page for each code
15. General issue	area code MED (one	per page)	
	ying issues Pharmaceuticals for Children Act [®] st Pharmaceuticals for Children Ac	e"	
Senate House	Congress and Federal agencies		☐ Check if None
16. Name of each	h individual who acted as a lob Name	byist in this issue	Covered Official Position (if applicable)
Eddie Evans			
Aventis SA is a s	SA. Aventis' interest is in extendir	nmercial law, head	6 above ☐ Check if None quartered in Strasbourg, France. Aventis Pharma reseach-based companies to conduct clinical trial
pediatric patients	5.		
Signature	S.		Date

FEEL.

egistrant Name	Aventis Pharmaceuticals Inc	Client Name	self
ngaged in lobbyi		uring the reporting peri	flect the general issue areas in which the riod. Using a separate page for each code
5. General issue	area code MED (one per page)	
assistance loai			of 2002 to clarify the rates applicable to marketing
17. House(s) of (Congress and Federal agend	cies contacted	Check if None
18. Name of eac	h individual who acted as a	lobbyist in this issue a	area Covered Official Position (if applicable)
18. Name of eac		lobbyist in this issue a	
		lobbyist in this issue a	
Eddie Evans Judy Cook		lobbyist in this issue a	
Eddie Evans Judy Cook			Covered Official Position (if applicable)
Eddie Evans Judy Cook 19. Interest of each	Name	c issues listed on line 16 a	Covered Official Position (if applicable)
Judy Cook 19. Interest of each Aventis SA is a second control of the control of	Name	c issues listed on line 16 a	Covered Official Position (if applicable)

Registrant Name	Aventis Pharmaceuticals Inc.	_ Client Name	self
engaged in lobbyi		the reporting pe	eflect the general issue areas in which the r riod. Using a separate page for each code
15. General issue	area code MED (one p	er page)	
16. Specific lobb S. 826 "Improv H.R. 1720 "Im All provisions	ying issues red Access to Osteoporosis Testing reproved Access to Osteoporosis Tes	Act of 2001" ting Act of 2001"	
17. House(s) of (Congress and Federal agencies c	ontacted	☐ Check if None
Senate House			<u>.</u>
18. Name of eac	h individual who acted as a lobb	yist in this issue	Covered Official Position (if applicable)
Judy Cook	, vario		СС 1000 СС 100

		••••	

		• • • • • • • • • • • • • • • • • • • •	

	ch foreign entity in the specific issu		•
			uartered in Strasbourg, France. Aventis Pharma could lead to early detection of individuals with o
Signature			Date
Printed Name and	Title Eddie D. Evans, VP, Feder	ral Government Re	lations

Registrant Name Aventis	Pharmaceuticals Inc.	Client Name_	self
	alf of the client during th	ne reporting p	o reflect the general issue areas in which the poeriod. Using a separate page for each code
15. General issue area code	e <u>CPT</u> (one per	page)	
2003"	al Development, Food and	_	ration and Related Agencies Appropriations Act, istrative role to FDA oversight role.
17. House(s) of Congress Senate Senate 18. Name of each individu			☐ Check if None
to. Name of Cach morvide	Name	st III tills 155u	Covered Official Position (if applicable)
	ration under French Comme	ercial law, head	.6 above ☐ Check if None dquartered in Strasbourg, France. Aventis Pharma
	me americanta to broteet intel	ilootaai propert	
SignatureE	ddie D. Evans, VP, Federal		Date

Form 1 D.2 (Rev 6/08) Filling #ea5a9673-317d-4fdc-8907-05ec7c842f6b - Page 19 of 28

Registrant Name	Aventis Pharmaceuticals Inc.	Client Name	self
engaged in lobbyi		g the reporting peri	flect the general issue areas in which the 1 iod. Using a separate page for each code
15. General issue	area code CPT (one p	oer page)	
16. Specific lobb	ying issues or Access to Affordable Pharmaceut	(
All provisions	er Access to Aπordable Pharmaceut	cais [.]	
17. House(s) of (Congress and Federal agencies of	contacted	☐ Check if None
18. Name of eac	h individual who acted as a lobl	oyist in this issue a	
	Name		Covered Official Position (if applicable)
Judy Cook		***	
Eddie Evans		•••	
		•	

19. Interest of each	th foreign entity in the specific issu	es listed on line 16 a	above Check if None
Aventis SA is a	stock corporation under French Con SA. Aventis' interest is to ensure t	nmercial law, headqu	nartered in Strasbourg, France. Aventis Pharma rug companies do not lose property protections
Signature			Date
Printed Name and			tions

Registrant Name	Aventis Pharmaceuticals Inc.	_ Client Name	self
engaged in lobbyin		the reporting perio	ect the general issue areas in which the i
15. General issue	area code MED (one p	er page)	
S. 2394 " A bill patients" All provisions		tic Act to require label	ing containing information applicable to pedia
17. House(s) of C	ongress and Federal agencies o	ontacted	Check if None
18. Name of each	individual who acted as a lobb	oyist in this issue ar	ea Covered Official Position (if applicable)
Judy Cook			
	h foreign entity in the specific issu	es listed on line 16 ab	ove
Aventis SA is a s	tock corporation under French Con	nmercial law, headqua	rtered in Strasbourg, France. Aventis Pharma d make on the "Best Pharmaceuticals for Chik
Signature	Tiela Eddie D. Evans, VP, Fede	ral Government Poloti	Date

LOBBYING ACTIVITY. Scleet as many codes as necessary to reflect the general issue areas in which the I engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed. 15. General issue area code HCR (one per page) 16. Specific lobbying issues S. 2328 "Safe Motherhood Act for Research and Treatment" All provisions 17. House(s) of Congress and Federal agencies contacted Check if None Senate Name Covered Official Position (if applicable) 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None Avents SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Avents Pharms is part of Aventis SA. Aventis Pharms is part of Aventis SA. Aventis Pharms is part of Aventis SA. Aventis Pharms regulatory agency have on-going. Also, the provision would add unprecedented ienforcements Signature Date	Registrant Name	Aventis Pharmaceuticals Inc.	_ Client Name	self
16. Specific lobbying issues S. 2328 "Safe Motherhood Act for Research and Treatment" All provisions 17. House(s) of Congress and Federal agencies contacted	engaged in lobbyii	ng on behalf of the client during	the reporting perio	
S. 2328 "Safe Motherhood Act for Research and Treatment" All provisions 17. House(s) of Congress and Federal agencies contacted	15. General issue	area code HCR (one pe	er page)	
Senate 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Judy Cook 19. Interest of each foreign entity in the specific issues listed on line 16 above Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharme is part of Aventis SA. Aventis is concerned that the bill would add unnecessary provisions that may duplicate programs regulatory agency have on-going. Also, the provision would add unprecedented tenforcemented.	S. 2328 "Safe I		eatment"	
Name Covered Official Position (if applicable) Judy Cook Judy Cook 19. Interest of each foreign entity in the specific issues listed on line 16 above Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharme is part of Aventis SA. Aventis is concerned that the bill would add unnecessary provisions that may duplicate programs regulatory agency have on-going. Also, the provision would add unprecedented inforcement		Congress and Federal agencies co	ontacted [☐ Check if None
Judy Cook 19. Interest of each foreign entity in the specific issues listed on line 16 above Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharma is part of Aventis SA. Aventis is concerned that the bill would add unnecessary provisions that may duplicate programs regulatory agency have on-going. Also, the provision would add unprecedented enforcement	18. Name of each	h individual who acted as a lobb	yist in this issue are	ea
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharma is part of Aventis SA. Aventis is concerned that the bill would add unnecessary provisions that may duplicate programs regulatory agency have on-going. Also, the provision would add unprecedented enforcement		Name	ŧ.	Covered Official Position (if applicable)
is part of Aventis SA. Aventis is concerned that the bill would add unnecessary provisions that may duplicate programs regulatory agency have on-going. Also, the provision would add unprecedented enforcement	19. Interest of each	-	•	•
SignatureDate	is part of Aventis	SA. Aventis is concerned that the b	ill would add unneces	sary provisions that may duplicate programs
·	Signature			Date

in the first record of

0. Client new address		,		

21. Client new principal plac				
City			tate/Zip (or Country)	
22. New general description	of client's busir	ess or activities		
		•		
LOBBYIST UPDAT 23. Name of each prev Donald A. Zowade	iously reporte	ed individual who is	no longer expected to act as a	lobbyist for the client
ISSUE UPDATE 24. General lobbying i			longer pertain	
AFFILIATED ORG 25. Add the following				
Nam	ne		Address	
Nam	ae		Address	
		ted organization tha	Address t is no longer affiliated with the	(city and state or co
	viously repor			(city and state or co
26. Name of each pre	viously repor			ness Amount of contribution
26. Name of each pre FOREIGN ENTITIE 27. Add the following	viously repor	ies	t is no longer affiliated with the	(city and state or co
26. Name of each pre FOREIGN ENTITIE 27. Add the following Name	viously repor	ies Address	t is no longer affiliated with the	(city and state or contribution for lobbying activities

----.

Filing #ea5a9673-317d-4fdc-8907-05ec7c842f6b - Page 28 of 28